Patrice Nordmann is an expert in Infectiology at University of Fribourg (Switzerland). Patrice Nordmann has authored 935 publications, the most recent in 2026, and is an investigator in 1 clinical trial. SLR score: 3,313 (community average: 125). How the SLR is computed.

LeadR Profile

Patrice Nordmann University of Fribourg Switzerland
3 313 ScienceLeadR Reputation 3313
Network Map

Infectiology

Subspecialties: Pharmacy - Genetics - Internal Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1989 - 2026

Source: PubMed

Bicêtre Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
In Vitro Synergistic Activity of Cefepime/Zidebactam Plus Aztreonam Against Metallo-β-Lactamase-Producing Enterobacterales.
PMID 42905289 — microbiology, aztreonam, cefepime
Curr Microbiol20260
Activity of oral β-lactams, tebipenem and ceftibuten, combined with novel oral β-lactamase inhibitors against broad-spectrum β-lactamase-producing Escherichia coli.
PMID 42905399 — escherichia, ceftibuten, drug therapy, escherichia coli, anti-bacterial agents, antiviral agents, lactams
Antimicrob Agents Chemother20260
Rapid ESBL-Carba Combo PN test for simultaneous detection of ESBL and carbapenemase activity in Enterobacterales.
PMID 42684917 — buffers, workflow, therapeutics, lactams, sensitivity and specificity
Microbiol Spectr20260
Phenotypic and biochemical characterization of the class C β-lactamase, PAC-1.
PMID 42639739 — genes, drug therapy, cephalosporins, lactams
J Antimicrob Chemother20260
Characterization of the intrinsic AmpC β-lactamase of Escherichia marmotae and its impact on decreased susceptibility to cefiderocol and resistance to broad-spectrum cephalosporins.
PMID 42591050 — escherichia, genes, amino acids, phenotype, drug therapy, enzymes, escherichia coli, cephalosporins, lactams
J Antimicrob Chemother20260

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 1

By status:

Unknown 1

By type:

Interventional 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 1
multicentric5to9 0
multicentricup10 0

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map